Skip to content

Dark Adaptation Testing to Identify AMD

ALSTAR Study: The Science Behind Dark Adaptation

The Alabama Study on Early Age-Related Macular Degeneration (ALSTAR study) tracked 325 adults age 60 and older. Each subject had normal macular health, as verified by clinical exam and grading of fundus photographs. When dark adaptation was assessed, 24% of subjects showed dark adaptation impairment at baseline.

Three years later, the subjects with impaired dark adaptation were two times more likely to have AMD and eight times more likely to have advanced beyond the earliest stage of AMD. In fact, the study showed a positive correlation between degree of dark adaptation impairment and severity of AMD. At the follow-up visit, all subjects with severe AMD were identified as having dark adaptation impairment at baseline.

The ALSTAR study was groundbreaking in that it demonstrated dark adaptation impairment indicates subclinical AMD at least three years before the disease is clinically evident.

 

It would be unimaginable nowadays to diagnose glaucoma without both structural and functional testing. With today’s technology, the same can be said for AMD as functional testing complements structural findings for the earliest indications of the disease

Leo Semmes, OD, FAAO Leo Semes, OD, FAAO View all testimonials

Functional Testing to Detect Subclinical AMD

Considering dark adaptation is impaired years before structural changes in the macula are observed, assessing dark adaptation function can be invaluable in detecting subclinical AMD. Identifying patients at the earliest stages of the disease allows for intervention when risk reduction strategies are most effective.

Improve Ability to Diagnose AMD

A landmark study published recently in JAMA Ophthalmology shows at least 25% of clinical AMD is going undiagnosed in primary eye care today. Moreover, 30% of the undiagnosed patients had large drusen, a known risk factor for advanced AMD (wet AMD). iii

Complementing structural exams with functional dark adaptation evaluation helps safeguard against failure to catch clinically-detectable AMD. Dark adaptation testing provides a clear, objective measure that is easy to interpret.

Ongoing Disease Management

For a patient with AMD, more frequent retinal exams are recommended to monitor disease progression—increasing from a 12-month to a six-month follow-up interval. More frequent visits and testing provide the clinician with a better chance to detect choroidal neovascularization (CNV) before visual acuity loss. For patients who are progressing rapidly or are at high risk for CNV, the follow-up visit interval may be shortened to every three or four months. Dark adaptation testing, together with structural tests like OCT, will help determine severity of the disease and desired frequency of follow up exams.

AdaptDx in grey square

Breakthrough in Dark Adaptation Testing

AdaptDx,® the only commercially available automated dark adaptometer, allows you to detect and monitor AMD in every day practice.

Hear from the AMD Experts

Videos

Eye care professionals explain why early detection of AMD matters.

Webinars

MacuLogix clinical advisers demonstrate how to improve AMD patient outcomes.